Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05247970 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess S-309309 in Healthy and Obese Participants
A Phase 1 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT05247970 is a Phase 1 study that has completed, run by Shionogi. The registered enrollment target is 74 participants.
The verdict
NCT05247970, a Phase 1 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The primary aim of the study is to assess the safety and tolerability of S-309309 after oral administration in healthy adult or obese but otherwise healthy adult participants. The secondary aim of the study is to assess the pharmacokinetics of S-309309 and the effects on ECG parameters after oral administration in healthy or obese but otherwise healthy participants.
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG S-309309
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05247970
The ClinicalTrials.gov registry entry for NCT05247970 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05247970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05247970 about?
NCT05247970 is a clinical study titled "A Study to Assess S-309309 in Healthy and Obese Participants". The primary aim of the study is to assess the safety and tolerability of S-309309 after oral administration in healthy adult or obese but otherwise healthy adult participants. The secondary aim of the study is to assess the pharmacokinetics of S-309309 and the effects on ECG parameters after oral ad...
What is the current status of trial NCT05247970?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2022-01-04. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT05247970?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), S-309309 (DRUG).
Who is sponsoring clinical trial NCT05247970?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.